Intuitive Surgical, Inc.
Intuitive Surgical Announces FDA Clearance for da Vinci 5
Summary
On March 14, 2024, Intuitive Surgical, Inc. announced the U.S. Food and Drug Administration (FDA) clearance of its fifth-generation robotic system, da Vinci 5. The new system features improved accuracy, a next-generation 3D display, force-sensing technology, workflow enhancements, and expanded computing power. Intuitive will hold a teleconference on March 18, 2024, to discuss the da Vinci 5 features and benefits and its launch plans. A press release regarding the clearance is furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for ISRG
Be first to know when Intuitive Surgical, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a pioneering company in the field of robotic-assisted, minimally invasive surgery. It is renowned for its development of the da Vinci Surgical System, which revolutionizes surgical procedures by enhancing precision, flexibility, and control beyond the physical capabilities of the human hand. The company's cornerstone product allows surgeons to perform complex surgeries through small incisions, which can lead to quicker patient recovery, reduced hospital stays, and lower complication rates. Operating predominantly in the healthcare sector, Intuitive Surgical serves a significant role in advancing surgical technology and improving patient outcomes. The company collaborates across diverse medical specialties, including urology, gynecology, and general surgery, to expand the applications and accessibility of its robust surgical systems. As an innovator in the medical device industry, Intuitive Surgical has a profound impact not only on surgical methodologies but also on the economic aspects of medical practices by potentially lowering surgical costs. It continues to shape the future of surgery with its commitment to enhancing robotic-assisted techniques.
Official SEC Documents
Advertisement